S&P 500   4,583.33 (-1.55%)
DOW   34,564.54 (-1.63%)
QQQ   392.09 (-1.90%)
AAPL   163.01 (+1.73%)
MSFT   330.65 (-1.78%)
FB   327.44 (-3.13%)
GOOGL   2,852.57 (-1.99%)
AMZN   3,499.99 (-1.73%)
TSLA   1,124.11 (-1.13%)
NVDA   321.29 (-3.74%)
BABA   126.39 (-3.97%)
NIO   38.44 (-4.99%)
CGC   10.33 (-6.60%)
AMD   156.88 (-3.11%)
GE   94.87 (-3.59%)
MU   84.70 (-1.67%)
T   22.56 (-5.57%)
F   19.11 (-2.85%)
DIS   143.60 (-2.85%)
ACB   6.13 (-4.81%)
AMC   33.25 (-9.74%)
PFE   53.57 (+2.23%)
BA   193.94 (-2.30%)
S&P 500   4,583.33 (-1.55%)
DOW   34,564.54 (-1.63%)
QQQ   392.09 (-1.90%)
AAPL   163.01 (+1.73%)
MSFT   330.65 (-1.78%)
FB   327.44 (-3.13%)
GOOGL   2,852.57 (-1.99%)
AMZN   3,499.99 (-1.73%)
TSLA   1,124.11 (-1.13%)
NVDA   321.29 (-3.74%)
BABA   126.39 (-3.97%)
NIO   38.44 (-4.99%)
CGC   10.33 (-6.60%)
AMD   156.88 (-3.11%)
GE   94.87 (-3.59%)
MU   84.70 (-1.67%)
T   22.56 (-5.57%)
F   19.11 (-2.85%)
DIS   143.60 (-2.85%)
ACB   6.13 (-4.81%)
AMC   33.25 (-9.74%)
PFE   53.57 (+2.23%)
BA   193.94 (-2.30%)
S&P 500   4,583.33 (-1.55%)
DOW   34,564.54 (-1.63%)
QQQ   392.09 (-1.90%)
AAPL   163.01 (+1.73%)
MSFT   330.65 (-1.78%)
FB   327.44 (-3.13%)
GOOGL   2,852.57 (-1.99%)
AMZN   3,499.99 (-1.73%)
TSLA   1,124.11 (-1.13%)
NVDA   321.29 (-3.74%)
BABA   126.39 (-3.97%)
NIO   38.44 (-4.99%)
CGC   10.33 (-6.60%)
AMD   156.88 (-3.11%)
GE   94.87 (-3.59%)
MU   84.70 (-1.67%)
T   22.56 (-5.57%)
F   19.11 (-2.85%)
DIS   143.60 (-2.85%)
ACB   6.13 (-4.81%)
AMC   33.25 (-9.74%)
PFE   53.57 (+2.23%)
BA   193.94 (-2.30%)
S&P 500   4,583.33 (-1.55%)
DOW   34,564.54 (-1.63%)
QQQ   392.09 (-1.90%)
AAPL   163.01 (+1.73%)
MSFT   330.65 (-1.78%)
FB   327.44 (-3.13%)
GOOGL   2,852.57 (-1.99%)
AMZN   3,499.99 (-1.73%)
TSLA   1,124.11 (-1.13%)
NVDA   321.29 (-3.74%)
BABA   126.39 (-3.97%)
NIO   38.44 (-4.99%)
CGC   10.33 (-6.60%)
AMD   156.88 (-3.11%)
GE   94.87 (-3.59%)
MU   84.70 (-1.67%)
T   22.56 (-5.57%)
F   19.11 (-2.85%)
DIS   143.60 (-2.85%)
ACB   6.13 (-4.81%)
AMC   33.25 (-9.74%)
PFE   53.57 (+2.23%)
BA   193.94 (-2.30%)
NASDAQ:APVO

Aptevo Therapeutics Stock Competitors

$10.35
-0.18 (-1.71%)
(As of 11/30/2021 12:16 PM ET)
Add
Compare
Today's Range
$9.50
$11.27
50-Day Range
$6.48
$17.49
52-Week Range
$6.38
$51.75
Volume
68,535 shs
Average Volume
9.99 million shs
Market Capitalization
$50.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
6.74

Aptevo Therapeutics (NASDAQ:APVO) Vs. PRTK, TNXP, ATNF, ATNX, MLND, INZY, ANVS, INFI, MBIO, and ALZN

Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Paratek Pharmaceuticals (PRTK), Tonix Pharmaceuticals (TNXP), 180 Life Sciences (ATNF), Athenex (ATNX), Millendo Therapeutics (MLND), Inozyme Pharma (INZY), Annovis Bio (ANVS), Infinity Pharmaceuticals (INFI), Mustang Bio (MBIO), and Alzamend Neuro (ALZN). These companies are all part of the "pharmaceutical preparations" industry.

Aptevo Therapeutics vs.

Tonix Pharmaceuticals (NASDAQ:TNXP) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Tonix Pharmaceuticals has a net margin of 0.00% compared to Aptevo Therapeutics' net margin of -265.80%. Tonix Pharmaceuticals' return on equity of -49.29% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals N/A -49.29% -46.53%
Aptevo Therapeutics -265.80% -248.45% -46.52%

In the previous week, Aptevo Therapeutics had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 4 mentions for Aptevo Therapeutics and 3 mentions for Tonix Pharmaceuticals. Tonix Pharmaceuticals' average media sentiment score of 0.00 beat Aptevo Therapeutics' score of -0.09 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tonix Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aptevo Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tonix Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 6.74, suggesting that its share price is 574% more volatile than the S&P 500.

Tonix Pharmaceuticals received 140 more outperform votes than Aptevo Therapeutics when rated by MarketBeat users. Likewise, 72.35% of users gave Tonix Pharmaceuticals an outperform vote while only 65.00% of users gave Aptevo Therapeutics an outperform vote.

CompanyUnderperformOutperform
Tonix PharmaceuticalsOutperform Votes
335
72.35%
Underperform Votes
128
27.65%
Aptevo TherapeuticsOutperform Votes
195
65.00%
Underperform Votes
105
35.00%

Tonix Pharmaceuticals currently has a consensus target price of $2.00, suggesting a potential upside of 337.45%. Aptevo Therapeutics has a consensus target price of $36.00, suggesting a potential upside of 266.97%. Given Tonix Pharmaceuticals' higher probable upside, research analysts clearly believe Tonix Pharmaceuticals is more favorable than Aptevo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aptevo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

20.8% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.5% of Aptevo Therapeutics shares are owned by institutional investors. 1.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 10.9% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aptevo Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tonix PharmaceuticalsN/AN/A-$50.46 million-$0.29-1.57
Aptevo Therapeutics$4.31 million11.77-$17.75 millionN/AN/A

Summary

Aptevo Therapeutics beats Tonix Pharmaceuticals on 7 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Aptevo Therapeutics (NASDAQ:APVO) vs. Its Competitors

TypeAptevo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$50.72M$5.81B$4.92B$7.86B
Dividend YieldN/A2.59%2.04%2.48%
P/E RatioN/A9.7819.1221.31
Price / Sales11.77560.832,526.07278.99
Price / CashN/A25.0141.51137.68
Price / Book2.7310.969.5510.62
Net Income-$17.75M$95.45M$95.24M$153.81M
7 Day Performance-39.22%-2.72%111.20%-2.99%
1 Month Performance-32.09%-9.83%106.76%-6.25%
1 Year Performance-76.33%15.77%160.84%30.07%

Aptevo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRTK
Paratek Pharmaceuticals
1.8981 of 5 stars
$4.11
-0.7%
$16.50
-301.5%
-33.2%$200.55M$46.92M-3.74197
TNXP
Tonix Pharmaceuticals
2.1181 of 5 stars
$0.46
-4.6%
$2.00
-338.5%
-16.6%$200.50MN/A-1.5726
ATNF
180 Life Sciences
1.8667 of 5 stars
$5.72
-0.2%
$11.00
-92.3%
+96.2%$194.59MN/A0.002Upcoming Earnings
News Coverage
Gap Up
ATNX
Athenex
2.1381 of 5 stars
$1.75
-1.7%
$6.83
-290.5%
-87.2%$191.31M$144.39M-1.20599Gap Down
MLND
Millendo Therapeutics
0 of 5 stars
$10.00
-4.0%
N/AN/A$190.43MN/A0.0012Gap Up
INZY
Inozyme Pharma
1.4331 of 5 stars
$7.83
-6.1%
N/A-68.3%$185.34MN/A0.0038Analyst Report
ANVS
Annovis Bio
2.3667 of 5 stars
$22.78
-7.2%
$70.00
-207.3%
N/A$184.52MN/A-16.162
INFI
Infinity Pharmaceuticals
1.6398 of 5 stars
$2.06
-1.5%
$9.56
-363.9%
+4.5%$183.36M$1.72M-3.6123Short Interest ↓
MBIO
Mustang Bio
1.9131 of 5 stars
$1.94
-3.1%
$10.33
-432.6%
-42.2%$181.25MN/A-2.2662
ALZN
Alzamend Neuro
2.0333 of 5 stars
$2.06
-7.8%
$11.50
-458.3%
N/A$178.99MN/A0.003Short Interest ↑
Gap Up
TFFP
TFF Pharmaceuticals
2.0914 of 5 stars
$6.98
-2.1%
$25.50
-265.3%
-55.3%$177.10MN/A-6.914Negative News
FREQ
Frequency Therapeutics
1.9865 of 5 stars
$5.06
-5.3%
$26.50
-423.7%
-81.4%$175.08M$36.98M-2.3585
DBTX
Decibel Therapeutics
2.3667 of 5 stars
$6.92
-0.3%
$22.00
-217.9%
N/A$172.45MN/A0.0040
NEXI
NexImmune
1.8448 of 5 stars
$7.58
-2.6%
$30.33
-300.2%
N/A$172.15MN/A0.0044Gap Up
OBSV
ObsEva
1.6781 of 5 stars
$2.18
-2.3%
$14.33
-557.5%
+8.8%$169.98M$20K-2.5645Analyst Report
Short Interest ↑
SCYX
SCYNEXIS
1.9514 of 5 stars
$7.07
-4.7%
$26.40
-273.4%
+9.6%$169.33M$120K-1.6038
SEEL
Seelos Therapeutics
1.8114 of 5 stars
$1.65
-5.5%
$10.20
-518.2%
+68.9%$168.94M$380K-2.7510
SYBX
Synlogic
2.4098 of 5 stars
$2.41
-0.4%
$9.83
-308.0%
-3.2%$168.00M$550K-1.8372
TERN
Terns Pharmaceuticals
1.9131 of 5 stars
$6.58
-1.4%
$26.50
-302.7%
N/A$166.26MN/A0.0030
NXTC
NextCure
1.9686 of 5 stars
$6.01
-0.3%
$16.67
-177.3%
-42.3%$166.03M$22.38M-2.4490
RPHM
Reneo Pharmaceuticals
2.1583 of 5 stars
$6.74
-4.0%
$34.75
-415.6%
N/A$164.62MN/A0.0018
LRMR
Larimar Therapeutics
1.4731 of 5 stars
$9.19
-3.6%
$29.50
-221.0%
-59.2%$162.76MN/A-2.7428
VIRX
Viracta Therapeutics
2.0333 of 5 stars
$4.32
-5.8%
$32.67
-656.2%
N/A$161.19M$120K0.008News Coverage
Gap Down
MNOV
MediciNova
1.9248 of 5 stars
$3.28
-4.3%
$15.00
-357.3%
-42.7%$160.85MN/A-14.269
MIST
Milestone Pharmaceuticals
1.9398 of 5 stars
$5.33
-5.1%
$20.00
-275.2%
-14.9%$159.10MN/A-6.2728
ANEB
Anebulo Pharmaceuticals
2.0333 of 5 stars
$6.66
-5.9%
$15.00
-125.2%
N/A$155.44MN/A0.002Gap Up
STSA
Satsuma Pharmaceuticals
2.6281 of 5 stars
$4.89
-7.4%
$10.38
-112.2%
+4.5%$154.18MN/A-2.4519Positive News
Gap Up
APTX
Aptinyx
2.3331 of 5 stars
$2.27
-2.6%
$8.00
-252.4%
-38.8%$153.72M$1.56M-2.2334Short Interest ↓
CRVS
Corvus Pharmaceuticals
2.5048 of 5 stars
$3.27
-5.5%
$4.83
-47.8%
-14.4%$152.22MN/A54.5042Short Interest ↓
Positive News
EQ
Equillium
2.2 of 5 stars
$5.12
-0.6%
$14.50
-183.2%
+4.7%$150.48MN/A-3.7931
BIVI
BioVie
2.0333 of 5 stars
$5.96
-10.7%
$50.00
-738.9%
-25.3%$148.76MN/A0.003Analyst Report
News Coverage
BCTX
BriaCell Therapeutics
0.1667 of 5 stars
$9.65
-5.3%
N/AN/A$148.32MN/A-11.49147,000Positive News
GALT
Galectin Therapeutics
2.2998 of 5 stars
$2.42
-2.9%
$14.00
-478.5%
-6.0%$143.60MN/A-4.486
ONCT
Oncternal Therapeutics
1.6331 of 5 stars
$2.89
-2.1%
$15.20
-426.0%
+10.5%$142.84M$3.38M-5.1613
SLGL
Sol-Gel Technologies
1.7115 of 5 stars
$6.92
-11.4%
$19.00
-174.6%
-16.3%$141.10M$8.77M-8.2465
NCNA
NuCana
1.7731 of 5 stars
$2.65
-5.3%
$9.00
-239.6%
-38.0%$138.23MN/A-2.352,020
BCEL
Atreca
2.3831 of 5 stars
$3.72
-6.2%
$24.50
-558.6%
-74.9%$138.20MN/A-1.33130
ZYNE
Zynerba Pharmaceuticals
1.6331 of 5 stars
$3.34
-5.4%
$10.56
-216.2%
-23.6%$137.67M$90K-3.0626
VBLT
Vascular Biogenics
1.6781 of 5 stars
$2.20
-5.5%
$5.75
-161.4%
+82.7%$137.21M$920K-4.3138
ONCR
Oncorus
2.6583 of 5 stars
$5.31
-3.6%
$35.00
-559.1%
-78.1%$137.05MN/A-2.2756
KZIA
Kazia Therapeutics
1.5715 of 5 stars
$10.15
-1.5%
$17.50
-72.4%
-1.8%$133.98M$11.35M0.002,021News Coverage
Positive News
XERS
Xeris Pharmaceuticals
2.2314 of 5 stars
$2.01
-1.5%
$6.42
-219.2%
-55.0%$133.66M$20.16M-1.33180Gap Up
DARE
Daré Bioscience
1.8114 of 5 stars
$1.74
-0.6%
$8.00
-359.8%
+29.6%$133.28MN/A-2.3520Short Interest ↓
RDHL
RedHill Biopharma
1.8114 of 5 stars
$2.80
-0.0%
$18.75
-569.6%
-68.4%$130.67M$64.36M-1.19182News Coverage
Gap Up
CFRX
ContraFect
1.9414 of 5 stars
$3.32
-3.0%
$11.75
-253.9%
-49.7%$130.58MN/A-4.8833Gap Up
Trading Halted
ENLV
Enlivex Therapeutics
1.7 of 5 stars
$6.94
-4.2%
$33.00
-375.5%
-16.1%$127.07MN/A-7.0850News Coverage
Positive News
PBYI
Puma Biotechnology
2.2964 of 5 stars
$3.10
-0.6%
$10.00
-222.6%
-73.7%$126.75M$225.10M-2.58267Negative News
Gap Down
SCPH
scPharmaceuticals
1.7131 of 5 stars
$4.54
-4.0%
$10.33
-127.6%
-50.1%$124.19MN/A-4.3727
SVRA
Savara
2.3714 of 5 stars
$1.09
-4.6%
$4.67
-328.1%
-14.3%$124.12M$260K0.00N/A
BLRX
BioLineRx
1.825 of 5 stars
$2.61
-1.5%
$14.50
-455.6%
+10.8%$123.87MN/A-2.072,020Short Interest ↑
This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.